All In MedTech

Device Trial Radar · NCT07688720

Transcutaneous Auricular Neurostimulation (tAN) for Premenstrual Dysphoric Disorder (PMDD) and Perimenopause

Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitation

Status

Enrolling by invitation

Enrollment

20

Planned (sponsor's estimate)

Start

Oct 22, 2026

Primary completion

Mar 2028

Study completion Jun 2028

Sponsor

Lead sponsor
Texas Christian UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Spark Biomedical, Inc.
First posted
Jul 7, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
Female only, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Transcutaneous Auricular Neurostimulation (tAN) will be administered to women with premenstrual syndrome (PMS), premenstrual dysphoric disorder (PMDD), and perimenopause. The investigators will examine whether tAN improves symptomology by collecting self-report data before the intervention, during the intervention, and following the intervention.

Conditions

  • Perimenopause
  • PMDD

Interventions

  • transcutaneous auricular neurostimulation (tAN)Device

    Device: Sparrow Link. The Sparrow Link will be using the components of the Sparrow Ascent device: (FDA-cleared K230796) a wearable, battery-operated, neurostimulation system designed to transcutaneously stimulate nerves on and/or around the auricle. This device will stimulate the auriculotemporal nerve (ATN) and the auricular branch of the vagus nerve (ABVN)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Daily Record of Severity of Problems (DRSP)Time frame: Assessed daily from study initiation until the end of the study, an average of four months (4 cycles). Menstrual cycle length varies but is generally 21-35 days.
  2. Green Climacteric ScaleTime frame: Participants will complete this measure monthly from study initiation until the end of the study, about three months.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Texas Christian University

    Fort Worth, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.